Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announces today that the 'QUID-NASH' project, in which it is a partner, is selected for the Academic Hospital-based Research in Health (RHU) call for health projects from the French governmental "Future Investment Program", that supports innovative large-scale projects in the field of health.

The QUID-NASH project aims to revolutionize the management of Non-Alcoholic SteatoHepatitis (NASH) - with 6 to 12% of the adult population affected - developing a virtual liver biopsy for a less invasive, more reliable diagnosis technique and a personalized patient care.

Intrasense provides its Myrian® platform for developing and industrializing the imaging research works of the project.

Supported by Pr. Dominique Valla, liver specialist at the French Institute of Medical Research (INSERM) in Paris, this project benefits from a funding worth €8.7 million and includes leading academic and industrial partners.

"We are very pleased to actively contribute to this great project" comments Stephane Chemouny, Chairman and Chief Executive Officer of Intrasense.

"Using Myrian® Studio in the framework of those research studies will allow the project team to save valuable time during the industrialization phase."

NASH, also called 'soft-drink disease', is a severe disease which can lead to cirrhosis and liver cancer. Epidemiologic studies show that one adult person out of 10 would be affected, due to a type-II diabetes or obesity often related to an abusive sugar consumption.

A huge market for the therapeutic industry - estimated from $20 to $40 billion per year - which could soon surpass the diabetes market*. More than a hundred companies are currently in competition to create molecules treating the disease.

* Source: BFM Business French TV program - 23/11/2017

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

For more information, please visitwww.intrasense.fr.

Intrasense

NewCap

Stéphane Chemouny

Investor Relations and Financial

Chairman and Chief Executive Officer

Communication

Christophe Lamboeuf

Valentine Brouchot

Deputy Managing Director

Pierre Laurent

Tel: +33 4 67 130 130

Tel: + 33 1 44 71 94 96

investor@intrasense.fr

intrasense@newcap.eu

Intrasense SA published this content on 09 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 January 2018 18:34:07 UTC.

Original documenthttp://www.intrasense.fr/wp-content/uploads/2018/01/PR_Intrasense_09012018_QUIDNASH_project.pdf

Public permalinkhttp://www.publicnow.com/view/E85D90B98B8D171EFDAB7563D0A86B08CDD3C712